Valeant increases Salix sales force by 40% to capture untapped market

It will make investment in primary care representatives for key products such as Xifaxan & Relistor

Premium

BS B2B Bureau Quebec, Canada

Last Updated : Feb 28 2017 | 1:56 PM IST

Valeant Pharmaceuticals International’s wholly owned subsidiary, Salix, has scaled up its sales force by nearly 40 percent, with immediate effective. Valeant had acquired gastrointestinal (GI) drugs specialist Salix in an all-cash deal for $ 10.1 billion in February 2015.

"This is a demonstration of our commitment to GI and its relative importance to the broader value of our company. The significant investments in Salix's dedicated primary care physician (PCP) sales force will help us further reach patients in need of irritable bowel syndrome with diarrhea (IBS-D) treatment, and in doing so, will further accelerate growth for our company," said Joseph Papa,

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in